Colorectal tumors can have innate and/or acquired chemoresistance, and each is important in determining initial and subsequent lines of systemic treatment. Innate resistance is typically noted during early drug development or in early phase clinical trials of biologic efficacy. Different mechanisms of acquired resistance can exist for each cytotoxic therapy and targeted pathway. However, acquired resistance to one drug often confers resistance to other drugs which may work by different mechanisms of action, a concept referred to as multidrug resistance. There is an urgent need for personalized medicine to select the optimal therapy from an expanding range of systemic treatment modalities in colorectal (CRC) patients. Therefore, the identification of biomarkers that could predict and/or monitor the response of CRC patients to a specific type of systemic therapy might shift the therapy towards precision medicine.
The main reason for the failure of cancer therapy is the uncontrollable, often unaccountable rapid development of drug resistance. Furthermore, in the process of acquiring resistance, the tumor may become cross-resistant to a range of chemotherapies which ultimately leads to treatment failure in over 90% of patients with metastatic disease. Strategies to overcome chemoresistance are urgently needed. The goal is to improve the efficacy of therapy and reduce toxicity in patients with a poor or favorable prognosis after systemic chemotherapy, and thus personalized treatment of CRC patients.
This Research Topic invites research as well as Review Articles that focus on chemoresistance in CRC patients and/or therapy resistance models. All the Original Research articles should comprehensively evaluate the biomarkers that could predict the response to a specific type of systemic therapy with a preferable focus on mechanistic insights using the patients´ samples or appropriate in vitro and/or in vivo models. Reviews should discuss in detail the chosen topic with enough illustrations and tabular data to comprehensively cover the topic.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Colorectal tumors can have innate and/or acquired chemoresistance, and each is important in determining initial and subsequent lines of systemic treatment. Innate resistance is typically noted during early drug development or in early phase clinical trials of biologic efficacy. Different mechanisms of acquired resistance can exist for each cytotoxic therapy and targeted pathway. However, acquired resistance to one drug often confers resistance to other drugs which may work by different mechanisms of action, a concept referred to as multidrug resistance. There is an urgent need for personalized medicine to select the optimal therapy from an expanding range of systemic treatment modalities in colorectal (CRC) patients. Therefore, the identification of biomarkers that could predict and/or monitor the response of CRC patients to a specific type of systemic therapy might shift the therapy towards precision medicine.
The main reason for the failure of cancer therapy is the uncontrollable, often unaccountable rapid development of drug resistance. Furthermore, in the process of acquiring resistance, the tumor may become cross-resistant to a range of chemotherapies which ultimately leads to treatment failure in over 90% of patients with metastatic disease. Strategies to overcome chemoresistance are urgently needed. The goal is to improve the efficacy of therapy and reduce toxicity in patients with a poor or favorable prognosis after systemic chemotherapy, and thus personalized treatment of CRC patients.
This Research Topic invites research as well as Review Articles that focus on chemoresistance in CRC patients and/or therapy resistance models. All the Original Research articles should comprehensively evaluate the biomarkers that could predict the response to a specific type of systemic therapy with a preferable focus on mechanistic insights using the patients´ samples or appropriate in vitro and/or in vivo models. Reviews should discuss in detail the chosen topic with enough illustrations and tabular data to comprehensively cover the topic.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
